IVD Overseas Registration: Reuse of Test Reports

Yes, IVD product test reports can be reused for overseas registration in certain circumstances, but this depends on the target country's regulatory requirements, the product risk class, the test standards applied, and the qualifications of the issuing laboratory. Enterprises must first determine whether the product falls within the medical device regulatory scope, then confirm the risk classification and registration pathway. Test reports previously obtained from China NMPA, EU CE, US FDA, or other mature markets can in principle be submitted as part of the technical documentation, but it is necessary to assess whether the test items cover the target country's requirements, whether the report format is accepted, and whether supplementary testing or updates are needed.

Key Summary

The reusability of IVD test reports for overseas registration is governed by the regulatory framework of the destination market, product risk level, differences in testing standards, and the credibility of the issuing body. Common risks include expired reports, version mismatches in testing standards, and missing country-specific supplemental items such as pathogen safety and sample stability. For multi-country registrations, building a core technical documentation package and harmonizing performance verification and risk management can significantly reduce duplicate testing costs. Post-market maintenance also requires close attention to report changes and evidence reuse for registration renewals.

Applicable Scenarios and Core Questions

In overseas IVD registration, reusing test reports is an important way to reduce cost and increase efficiency. Typical scenarios include using domestic registration test reports, CE technical file performance evaluation reports, or FDA 510(k) comparative data for applications in other countries. The core questions are: Does the target country accept reports issued outside its jurisdiction? Which tests must be repeated locally? What are the validity periods and formatting requirements?

Regulatory systems differ significantly across countries. GHWP members such as ASEAN countries, Saudi Arabia, and Brazil generally accept laboratory reports accredited to ISO 17025, but some countries require local testing or additional items. For example, Brazil's ANVISA requires certain infectious pathogen testing reports to be completed by laboratories located in Brazil. China's NMPA requires initial registration test reports to be issued by a qualified domestic laboratory. Therefore, it is essential to confirm the rules on a country-by-country basis before reusing any report.

Registration Decision Logic

Step 1: Confirm Regulatory Scope

Determine whether the product falls under the target country's medical device regulatory scope. IVD classification systems differ: the EU IVDR classifies products as A, B, C, or D; China uses risk-based classification; and the US FDA treats IVDs as medical devices with a three-class system. If the product is not considered a medical device, the rules for test report reuse may differ.

Step 2: Determine Risk Class and Registration Path

High-risk products such as HIV test kits typically require more rigorous performance verification and clinical evaluation. Low-risk devices like pH test strips may only need basic performance reports. The registration route—whether direct registration, through an authorized representative, or via a local agent—also affects the test report requirements.

Step 3: Assess Technical Compliance

Check whether existing test reports satisfy target country technical requirements. Key points include whether the standard version is current, whether sample size is sufficient, whether reagent lots are adequately covered, whether stability study duration is appropriate, and whether analytical performance parameters are complete. For example, CE IVDR requires clinical performance evaluation, while China may additionally require full data sets for precision, sensitivity, and specificity.

Step 4: Verify Laboratory Accreditation

Most countries require testing laboratories to be accredited to ISO 17025 or an equivalent quality system, or to be a recognized international body such as CNAS, CLIA, or an EU Notified Body designated laboratory. Reports from non-accredited laboratories are usually not accepted.

Documentation and Evidence

Reusable test report types include analytical performance reports (precision, linearity, recovery), stability reports (long-term, accelerated, transport simulation), clinical evaluation or trial reports (sensitivity and specificity), reference interval establishment reports, and metrological traceability reports. Evidence must show that the reports comply with target country standards and that the issuing laboratory's accreditation is valid.

Items requiring localization include labeling and instructions for use (language, symbols, format), packaging specifications, local agent declarations, authorizations, and quality system certificates such as ISO 13485 or MDSAP. Risk management reports created under ISO 14971 are often reusable, but target country-specific risk analyses may need to be added.

For multi-country registration, it is advisable to build a Common Technical Document (CTD) package that includes product description, intended use, design verification, performance data, risk management, clinical evaluation, and stability information. Then supplement localized content for each country to avoid recompiling the same data from scratch.

Common Mistakes

• Assuming CE or FDA reports are universally accepted, ignoring differences in standard versions and supplementary test needs.
• Overlooking report validity and using reports older than five years (or three years in some countries), which leads to rejected submissions.
• Submitting reports from laboratories not recognized by the target country, such as factory self-test reports lacking ISO 17025 accreditation.
• Not addressing local biological safety testing requirements (e.g., HBV, HCV, HIV) where some countries require repeat testing in local laboratories.
• Mixing up registration pathways, such as trying to register a Class III product through the Class II self-test route, resulting in deficiency notifications or rejection.
• Failing to retain original test records, protocols, and deviation reports, making it impossible to verify the authenticity of test reports during regulatory review.

Enterprise Preparation Checklist

• Compile a list of target countries and collect their registration guidance and testing requirements.
• Establish a database of existing test reports, noting report number, test item, issuing body, validity date, and standard used.
• Compare country-specific differences and identify tests that must be added.
• Evaluate whether laboratory accreditations meet target country expectations, and engage internationally recognized third-party laboratories when needed.
• Prepare a CTD-style technical file package with version control and traceability of changes.
• Confirm whether your local agent or authorized representative is responsible for managing test reports, as in Brazil RDC 830, where the local holder is required to handle report updates.
• Develop a multi-country timeline that prioritizes common testing before addressing country-specific items.
• Monitor regulatory updates, such as EU IVDR transition periods and Thai FDA updates, to reassess report validity on an ongoing basis.

AIMEILI Perspective

One of the most common misjudgments is assuming that test reports are universally valid because they come from CE or FDA. In reality, regulatory differences between countries are substantial. To avoid late-stage deficiencies and additional costs, enterprises should conduct a gap analysis early in the project to identify country-specific requirements.

Three priority actions are recommended: first, establish a global product registration archive that lists all completed test items and the relevant standard versions; second, use laboratories that are ISO 17025 accredited and cover multiple standards such as CLSI, ISO, and NCCLS to improve report reusability; third, work closely with local agents or consultants to reach an advance agreement on acceptable reports.

Core reusable materials include analytical performance, stability, risk management, and clinical data—provided the study design is sound and the population is comparable. Items that must be localized typically include labeling and instructions for use, language translation, local registration format conversion, and local clinical evaluation addressing specific ethnic or epidemiological differences.

The local agent is not merely a registration representative; they also oversee certificate control, change notifications, and post-market surveillance. Enterprises should carefully vet an agent's qualifications and responsiveness to avoid certificate invalidation due to agent negligence. For multi-country registrations, keep all test report originals, translations, authorizations, quality system certificates, and technical files in one system using a document management platform. This enables rapid retrieval for modifications and renewals and reduces the risk of repeated compilation and corrections.

Frequently Asked Questions

Do test reports have an expiration date? Can expired reports be reused?

Most countries require test reports to be valid at the time of application for registration. The validity period is typically two to five years depending on the test item. Stability reports must cover the intended shelf life at the time of application. Expired reports cannot be reused directly, but they can be used as historical evidence; it is advisable to conduct new testing or provide extended stability data.

Can NMPA test reports be used directly for Southeast Asian registration?

Some Southeast Asian countries, such as Singapore, Thailand, and Malaysia, accept reports from CNAS-accredited laboratories, but it is necessary to confirm whether the testing standards align. Some countries require testing for additional parameters relevant to local public health, such as dengue serotyping. Consult a local agent on a country-by-country basis.

What should be done if a test report is lost or original data cannot be obtained?

Try contacting the original testing institution to issue a duplicate report or a verification statement. If the original report cannot be recovered, key performance tests must be repeated. Enterprises should implement a robust report archiving system to prevent loss.

Do test reports need to be translated for multi-country registration? Are certified translations required?

Most countries require translations in the local official language. Some countries, such as Brazil, require sworn translation by a certified public translator (Traductor Público). Check in advance whether consular legalization or an apostille is necessary.

Continue Reading

For further guidance, we recommend the following related articles:

• How to Prepare Clinical Evaluation Dossiers for IVD Overseas Registration
• Using ISO 13485 Certificates for IVD Overseas Registration
• Medical Device Registration in Australia: Reuse of Test Reports
• Medical Device Registration in Australia: Use of ISO 13485 Certificates
• How to Select a Local Agent for Australian Medical Device Registration
• Allocation of Responsibilities for Authorized Representatives in Australia
• Why Medical Device Registration Timelines Are Extended in Australia
• Common Causes of Deficiency Notifications for Australian Medical Device Submissions

Content Review and Applicability

Content author: AIMEILI Regulatory Editorial Team. Professional review: AIMEILI Medical Device International Registration Project Group. Source principle: priority is given to official regulatory bodies, international organizations, standards organizations, and publicly available regulatory materials; industry media and project experience are used only for auxiliary judgment. Applicability: this article is intended for preliminary understanding, documentation preparation, and project planning, and does not replace the formal requirements of the target country's regulatory authority, testing conclusions, or legal advice.